2. Apodaca G. The uroepithelium: not just a passive barrier. Traffic.2004;5:117–128.

3. Birder L.A., et al. Altered urinary bladder function in mice lacking the vanilloid receptor TRPV1. Nature Neurosci.2002;5:856–860.

4. Buckner S.A., Milicic I., Daza A.V., Coghlan M.J., Gopalakrishnan M. Spontaneous phasic activity of the pig urinary bladder smooth muscle: characteristics and sensitivity to potassium channel modulators. Br J Pharmacol. 135.2005; 639–648.

5. Tyagi S., et al. Qualitative and quantitative expression profile of muscarinic receptors in human urothelium and detrusor. J Urol2006;176:1673–1678.

6. Hawthorn M.H, Chapple C.R., Cock M., Chess-Williams R. Urothelium-derived inhibitory factor(s)influences on detrusor muscle contractility in vitro. Br J Pharmacol.2000;129:416–419.

7. Braverman A.S., Lebed B., Linder M., Ruggieri M.R. M2 mediated contractions of human bladder from organ donors is associated with an increase in urothelial muscarinic receptors. NeurourolUrodyn 2007; 26:63–70.

8. Kanai A., et al. Origin of spontaneous activity in neonatal and adult rat bladders and its enhancement by stretch and muscarinic agonists. Am J Physiol.2007;292:1065–1072.

9. Birder L.A., Wolf-Johnston A.S., Sun Y., Chai T.C. Alteration in TRPV1 and muscarinic M3 receptor expression and function in idiopathic overactive bladder urothelial cells. ActaPhysiol (Oxf).2013;207:123–129.

10. Moldwin R., Kitt M., Mangel J., Beyer R., Hanno P., Butera P., et al. A phase 2 study in women with interstitial cystitis/bladder pain syndrome (IC/BPS) of the novel p2x3 antagonist AF219. Paper presented at the 45th Annual meeing of international contionence society. 2015; 6–9.

11. Gillespie J.I., Marerink-van Ittersum M., de Vente J. Expression of neuronal nitric oxide synthase (nNOS) and nitric-oxide-induced changes in cGMP in the urothelial layer of the guinea pig bladder.Cell Tissue Res. 2005;321:341–351.

12. Aizawa N., Igawa Y., Nishizawa O., Wyndaele J.J. Effects of nitric oxide on the primary bladder afferent activities of the rat with and without intravesicalacrolein treatment. Eur Urol. 2011;59:264–271.

13. Minagawa T., Aizawa N., Igawa Y., Wyndaele J.J. Inhibitory effects of phosphodiesterase 5 inhibitor, tadalafil, on mechanosensitive bladder afferent nerve activities of the rat, and on acrolein-induced hyperactivity of these nerves. BJU Int. 2012;110:259–266.

14. Wakabayashi Y., Tomoyoshi T., Fujimiua M., Arai R., Maeda T. Substance P-containing axon terminals in the mucosa of the human urinary bladder: preembedding immunohistochemistry using cryostat sections for electron microscopy. Histochemistry 1993;100:401–407.

15. Burbach G.J., Kim K.H., Zivony A.S., et al. The neurosensory tachykinins substance P and neurokinin A directly induce keratinocyte nerve growth factor. J Invest Dermatol 2001;117:1075–1082.

16. Paukert M., Osteroth R., Geisler H.S., et al. Inflammatory mediators potentiate ATP-gated channels through the P2X(3) subunit. J BiolChem.2001;276:210:77–82.

17. Kiss S., Yoshiyama M., Cao Y.Q., et al. Impaired response to chemical irritation of the urinary tract in mice with disruption of the preprotachykinin gene. NeurosciLett. 2001;313:57–60.

18. Krivoborodov G.G., Kolesanova E.F., Tur E.I., Efremov N.S. Nerve growth factor in patients with idiopathic detrusor hyperactivity and overactive bladder without detrusor hyperactivity. Urology. 2015;3: 19–22. Russian (Кривобородов Г.Г., Колесанова Е.Ф., Тур Е.И., Ефремов Н.С. Фактор роста нервов у больных с идиопатической детрузорной гиперактивностью и гиперактивным мочевым пузырем без детрузорной гиперактивности.Урология. 2015; 3:19–22).

19. Brading A.F., Brain K.L.Ion channel modulators and urinary tract function. HandbExpPharmacol.2011; 202: 375–393.

20. Janssen D.A., Hoenderop J.G., Jansen K.C., Kemp A.W., Heesakkers J.P., Schalken J.A. The mechanoreceptor TRPV4 is localized in adherence junctions of the human bladder urothelium: a morphological study. J Urol. 2011;186:1121–1127.

21. Gevaert T., Vriens J., Segal A., Everaerts W., Roskams T., Talavera K, et al. Deletion of the transient receptor potential cation channel TRPV4 impairs murine bladder voiding. J Clin Invest. 2007;117:3453–3462.

22. Everaerts W., Zhen X., Ghosh D., Vriens J., Gevaert T., Gilbert JP, et al. Inhibition of the cation channel TRPV4 improves bladder function in mice and rats with cyclophosphamide-induced cystitis. Proc Natl AcadSci USA. 2010;107:184–189.

23. Deruyver Y., Voets T., De Ridder D., Everaerts W. Transient receptor potential channel modulators as pharmacological treatments for lower urinary tract symptoms (LUTS): myth or reality? BJU Int. 2015;115:686–697.

24. LiaoL, MadersbacherH. Neurourology: Theory and Practice. 2019. P. 27.

25. Sui G.P., Rothery S., Dupont E., Fry C. H., Severs N.J. Gap junctions and connexin expression in human suburothelial interstitial cells. BJU Int. 2002; 90:118–129.

26. Koh B.H. Platelet-derived growth factor receptor-α cells in mouse urinary bladder: a new class of interstitial cells. J Cell Mol Med.2012;16(4):691–700.

27. Koh S.D. The Mystery of the Interstitial Cells in the Urinary.Annu Rev PharmacolToxicol.2018;58:603–623.

28. Kuijpers K.A., Heesakkers J.P., Jansen C.F., SchalkenJ.A.Cadherin-11 is expressed in detrusor smooth muscle cells and myofibroblasts of normal human bladder. EurUrol2007;52:1213–1221.

29. Roosen A., Apostolidis A., Elneil S., et al. Cadherin-11 up-regulation in overactive bladder suburothelial myofibroblasts. JUrol2009;182:190–195.

30. Cassimeris L., Lingappa V.R., Plopper D. Lewin Cells. M.: Laboratory of knowledge. 2016; 1056. Russian (Кассимерис Л.,Лингаппа В.Р., Плоппер Д. КлеткипоЛьюину. М.: Лаборатория знаний. 2016; 1056).

31. Chancellor M.B., Fowler C.J., Apostolidis A., de Groat W.C., Smith C.P., Somogyi G.T., et al. Drug insight: biological effects of botulinum toxin A in the lower urinary tract. Nat ClinPract Urol. 2008;5:319–328.

32. Humeau Y., Doussau F., Grant N.J., Poulain B. How botulinum and tetanus neurotoxins block neurotransmitter release. Biochimie.2000;82:427–446.

33. Liu H.T., Chancellor M.B., Kuo H.C. Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. Eur Urol. 2009;56:700–706.

34. Apostolidis A., Popat R., Yiangou Y., Cockayne D., Ford A.P., Davis J.B., et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol. 2005;174:982–983.

35. Morenilla-Palao C., Planells-Cases R., Garcнa-Sanz N., Ferrer-Montiel A.Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity. J Biol Chem. 2004;279:25665–25672.

36. De Paiva A., Meunier F.A., Molgу J., Aoki K.R., Dolly J.O. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl AcadSci USA. 1999;16:3200–3205.

37. Mangera A., Andersson K.E., Apostolidis A., et al. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxin A) and disport (abobotulinumtoxin A). Eur Urol. 2011;60:784–795.

38. Tyagi P., Kashyap M., Yoshimura N., et al. Past, present and future of chemodenervation with botulinum toxin in the treatment of overactive bladder. J Urol. 2017;197:982–990.

39. Kajbafzadeh A.M., Ahmadi H., Montaser-Kouhsari L., et al. Intravesical electromotive botulinum toxin type AadministrationpartII: clinical application. Urology. 2011;77:439–445.

40. Ladi-Seyedian S.S., Sharifi-Rad L., Kajbafzadeh A.M. Intravesical electromotive botulinum toxin type “A” administration for management of urinary incontinence secondary to neuropathic detrusor overactivity in children: long-term follow-up. Urology.2018;114:167–174.

41. Rajaganapathy B.R., Chancellor M.B., Nirmal J., et al. Bladder uptake of liposomes after intravesical administration occurs by endocytosis. PLoS One. 2015;10:e0122766.

42. de Paiva A., Dolly J.O. Light chain of botulinum neurotoxin is active in mammalian motor nerve terminals when delivered via liposomes. FEBS Lett. 1990;277:171–174.

43. Janicki J.J., Chancellor M.B., Kaufman J, et al. Potential effect of liposomes and liposome-encapsulated botulinum toxin and tacrolimus in the treatment of bladder dysfunction.Toxins (Basel). 2016;8:81.

44. Kuo H.C., Liu H.T., Chuang Y.C., et al. Pilot study of liposome-encapsulated onabotulinumtoxina for patients with overactive bladder: a single-center study. Eur Urol. 2014;65:1117–1124.

45. Chuang Y.C., Kaufmann J.H., Chancellor D.D., et al. Bladder instillation of liposome encapsulated onabotulinumtoxina improves overactive bladder symptoms: a prospective, multicenter, double-blind, randomized trial. J Urol. 2014;192:1743–1749.

46. Peters K.M., Hasenau D., Killinger K.A., et al. Liposomal bladder instillations for IC/BPS: an open-label clinical evaluation. IntUrolNephrol. 2014;46:2291–95.

47. Chuang Y.C., Kuo H.C. A prospective, multicenter, double-blind, randomized trial of bladder instillation of liposome formulation onabotulinumtoxin A for interstitial cystitis/bladder pain syndrome. J Urol. 2017;198(2):376–382.

48. Stav K., Vinshtok Y., Jeshurun M., et al. PD20–03 pilot study evaluating safety and feasibility of intravesical instillation of botulinum toxin in hydrogel-based slow release delivery system in PBS/IC patients. J Urol Suppl. 2015;193:398.

49. Krhut J., Navratilova M., Sykora R., et al. Intravesical instillation of onabotulinum toxin A embedded in inert hydrogel in the treatment of idiopathic overactive bladder: a double-blind randomized pilot study. Scand J Urol. 2016;50:200–205.

50. Chess-Williams R., Chapple C.R., Yamanishi T., Yasuda K., Sellers D.J. The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro. J AutPharmacol. 2001;21(5–6):243–248.

51. Fetscher C., Fleichman M., Schmidt M., Krege S., Michel M.C. M3 muscarinic receptors mediate contraction of human urinary bladder. Br J Pharmacol. 2002;136(5):641–643.

52. Finney S.M., Andersson K.E., Gillespie J.I., Stewart L.H. Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions? BJU Int. 2006;98(3):503–507.

53. de Groat W.C., Downie J.W., Levin R.M., Long Lin A.T., Morrison J.F.B., Nishizawa O., et al. Basic neurophysiology and neuropharmacology. In: Abrams PKS, Wein A, editor. Incontinence: 1st International Consultation on Incontinence. Plymouth: Plymbridge Distributors Ltd; 1999;105–154.

54. Yoshida M., Masunaga K., Satoji Y., Maeda Y., Nagata T., Inadome A. Basic and clinical aspects of non-neuronal acetylcholine: expression of non-neuronal acetylcholine in urothelium and its clinical significance. J Pharmacol Sci. 2008;106(2):193–198.

55. Tatsuya H.A.G.A..Molecular properties of muscarinic acetylcholine receptors / Proc JpnAcadSer B Phys Biol Sci. 2013;89(6): 226–256.

56. Katzung B.G. Basic and Clinical Pharmacology -13th Ed. Lange. P. 38–40.

57. John G. Nicholls., A. Robert Martin., Bruce G. Wallace., Paul A. Fuchs. »From neuron to brain», 4th.edn. Sinauer, 2001.

58. Andersson K.E. New pharmacologic targets for the treatment of the overactive bladder: an update. Urology. 2004;1:32–41.

59. Compion G., Jackson J., Janes J. Reasons for switching antimuscarinic therapy: Results from a European cross-sectional survey of physicians and patients with OAB. European Urology Supplements. 2012; 11(1):691–96.

60. Rapp D.E., Lyon M.B., Bales G.T., et al. A role for the P2X receptor in urinary tract physiology and in the pathophysiology of urinarydysfunction.Eur Urol. 2005;48:303–308.